German Multicenter Study Investigating Lu 177-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

Kambiz Rahbar*, Hojjat Ahmadzadehfar, Clemens Kratochwil, Uwe Haberkorn, Michael Schaefers, Markus Essler, Richard P. Baum, Harshad R. Kulkarni, Matthias Schmidt, Alexander Drzezga, Peter Bartenstein, Andreas Pfestroff, Markus Luster, Ulf Luetzen, Marlies Marx, Vikas Prasad, Winfried Brenner, Alexander Heinzel, Felix M. Mottaghy, Juri RufPhilipp Tobias Meyer, Martin Heuschkel, Maria Eveslage, Martin Boegemann, Wolfgang Peter Fendler, Bernd Joachim Krause

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)85-90
Number of pages6
JournalJournal of Nuclear Medicine
Volume58
Issue number1
DOIs
Publication statusPublished - Jan 2017

Keywords

  • prostate cancer
  • PSMA-617
  • mCRPC
  • radioligand therapy
  • GA-68-PSMA LIGAND
  • CLINICAL-TRIALS
  • PSMA
  • ENZALUTAMIDE
  • ABIRATERONE
  • STATISTICS
  • DOCETAXEL
  • PET/CT

Cite this

Rahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schaefers, M., Essler, M., Baum, R. P., Kulkarni, H. R., Schmidt, M., Drzezga, A., Bartenstein, P., Pfestroff, A., Luster, M., Luetzen, U., Marx, M., Prasad, V., Brenner, W., Heinzel, A., Mottaghy, F. M., ... Krause, B. J. (2017). German Multicenter Study Investigating Lu 177-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. Journal of Nuclear Medicine, 58(1), 85-90. https://doi.org/10.2967/jnumed.116.183194